Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dynamic nature of BRAF or KRAS p.G12C mutations in second-line therapy for advanced colorectal cancer patients: do early and late effects exist?

British journal of cancer - 1 Mar 2024

Contreras-Toledo Débora, Jiménez-Fonseca Paula, López Carlos López, Montes Ana Fernández, López Muñoz Ana María, Vázquez Rivera Francisca, Alonso Vicente, Alcaide Julia, Salvà Francesc, Covela Rúa Marta, Guillot Mónica, Martín Carnicero Alfonso, Jimeno Mate Raquel, Cameselle García Soledad, Asensio Martínez Elena, González Astorga Beatriz, Fernandez-Diaz Amaya B, González Villaroel Paula, Virgili Manrique Anna C, Melián Sosa Marcos, Alonso Beatriz, Cousillas Castiñeiras Antia, Castañón López Carmen, Aparicio Jorge, Carmona-Bayonas Alberto

Abstract excerpt

INTRODUCTION: The mitogen-activated protein kinase (MAPK) signalling network aberrations in metastatic colorectal cancer (mCRC) generate intrinsic dynamic effects and temporal variations that are crucial but often overlooked in clinical trial populations. Here, we investigate the time-varying impact of MAPK pathway mutation genotype on each treatment line's contribution to the overall clinical course. METHODS:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Colonic Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Colorectal Neoplasms

Share to Disease Progression

Share to Mutation

Share to Proto-Oncogene Proteins B-raf

Share to Proto-Oncogene Proteins p21(ras)

Source

Open in PubMed Open full text

Identifiers

PMID: 38191609
DOI: 10.1038/s41416-023-02563-w
PMCID: PMC10912758

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dynamic nature of BRAF or KRAS p.G12C mutations in second-line therapy for advanced colorectal cancer patients: do early and late effects exist?PMID 38191609Read ↗

Real-world treatment patterns and outcomes based on RAS/BRAF status in metastatic colorectal cancer-Analysis of the Prospective Dutch Colorectal Cancer cohort.Semantic proximity Read ↗

Real-World Study of Characteristics and Treatment Outcomes Among Patients with KRAS p.G12C-Mutated or Other KRAS Mutated Metastatic Colorectal Cancer.Semantic proximity Read ↗

Relevance of primary lesion location, tumour heterogeneity and genetic mutation demonstrated through tumour growth inhibition and overall survival modelling in metastatic colorectal cancer.Semantic proximity Read ↗

Dynamics in treatment response and disease progression of metastatic colorectal cancer (mCRC) patients with focus on BRAF status and primary tumor location: analysis of untreated RAS-wild-type mCRC patients receiving FOLFOXIRI either with or without panitumumab in the VOLFI trial (AIO KRK0109).Semantic proximity Read ↗

The prevalent KRAS exon 2 c.35 G>A mutation in metastatic colorectal cancer patients: A biomarker of worse prognosis and potential benefit of bevacizumab-containing intensive regimens?Semantic proximity Read ↗

Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials.Semantic proximity Read ↗

The long-term survival characteristics of a cohort of colorectal cancer patients and baseline variables associated with survival outcomes with or without time-varying effectsSemantic proximity Read ↗

Anti-cancer treatment schedule optimization based on tumor dynamics modelling incorporating evolving resistance.Semantic proximity Read ↗

Early ctDNA Dynamics Predict Response to Mosperafenib in BRAF V600-Mutant Metastatic Colorectal Cancer.Semantic proximity Read ↗

Why tyrosine kinase inhibitor resistance is common in advanced gastrointestinal stromal tumorsSemantic proximity Read ↗

Evaluation of survival across several treatment lines in metastatic colorectal cancer: Analysis of the FIRE-3 trial (AIO KRK0306).Semantic proximity Read ↗

Conditional prediction of consecutive tumor evolution using cancer progression models: What genotype comes next?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.